NCT05309421View on ClinicalTrials.gov

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

March 30, 2026

Conditions
Melanoma Stage IVUnresectable Melanoma
Interventions
DRUG

EVX-01

Investigational drug given in combination with standard of care

DRUG

Pembrolizumab 25 MG/ML

Standard of care

Trial Locations (4)

2065

Melanoma Institute Australia, Wollstonecraft

6009

One Clinical Research, Nedlands

Unknown

Divisione di Oncologia Medica del Melanoma, Milan

Instituto Nazionale Tumori IRCCS Fondazione, Napoli

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Evaxion Biotech A/S

INDUSTRY

NCT05309421 - A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter